Conditions: Pneumonia, Bacterial
Keywords: ampicillin sodium/sulbactam sodium Unasyn-S community acquired pneumonia bacterial pneumonia
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: no

Brief summary:
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.

Detailed description:

Arms:
arm 1: ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV

Interventions: intervention 1: ampicillin sodium/sulbactam sodium
Intervention descriptions: intervention 1: ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days

Protocol document: